1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

Final

Contact:
Monique N. Dolecki, Investor Relations — 201-847-5453
Colleen T. White, Corporate Communications — 201-847-5369

BD ANNOUNCES RESULTS FOR 2011 THIRD FISCAL QUARTER

Franklin Lakes, NJ (August 2, 2011) — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.014 billion for the third fiscal quarter ended June 30, 2011, representing an increase of 10.0 percent from the prior-year period. On a foreign currency-neutral basis, revenues increased 4.8 percent.

“We are pleased with our solid results this quarter, with all three segments contributing to growth,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “Gross margin expansion reflecting favorable product mix has offset some of the headwinds we have been facing as a result of a challenging macroeconomic environment and increased raw material costs.”

Agreement to Acquire Carmel Pharma, AB

On July 27, 2011, the Company announced that it had signed a definitive agreement to acquire Carmel Pharma, AB, a Swedish company that manufactures the PhaSeal^® System. This is the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials. The acquisition is expected to close prior to the end of this fiscal year.

Third Quarter and Nine-Month Fiscal 2011 Operating Results

Reported diluted earnings per share from continuing operations for the third quarter were $1.51, compared with $1.23 in the prior-year period, representing a 22.8 percent increase, or 13.8 percent on a currency-neutral basis.

For the nine-month period ending June 30, 2011, reported diluted earnings per share from continuing operations were $4.23, compared with $3.66 in the prior-year period. The prior-year period included a non-cash charge of $8.9 million, or $0.04 per share, related to healthcare reform impacting Medicare Part D reimbursements. Excluding that item, earnings per share from continuing operations increased by 14.3 percent, compared with adjusted diluted earnings per share from continuing operations of $3.70 in the prior-year period, or 8.1 percent on a currency-neutral basis.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.045 billion, representing an increase of 10.5 percent compared with the prior-year period, or 4.9 percent on a foreign currency-neutral basis. Revenues reflected strong sales of Pharmaceutical Systems products and international

safety, along with solid sales of Diabetes Care products. For the nine-month period ended June 30, 2011, BD Medical revenues increased 4.0 percent, or 1.7 percent on a foreign currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $631 million, representing an increase of 9.6 percent compared with the prior-year period, or 4.8 percent on a foreign currency-neutral basis. Revenues reflected solid growth in Preanalytical Systems safety-engineered products and strong growth in both the Women’s Health and Cancer and the Infectious Disease product offerings in the Diagnostics Systems unit. For the nine-month period ended June 30, 2011, BD Diagnostics revenues increased 6.4 percent, or 3.9 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $338 million, representing an increase of 9.3 percent compared with the prior-year period, or 4.3 percent on a foreign currency-neutral basis. Segment growth was driven primarily by instrument and reagent sales in the Cell Analysis unit. Discovery Labware revenues in the U.S. were negatively impacted by weakness in core consumables. The segment’s revenues also reflected softness in Western Europe due to government research funding delays. For the nine-month period ended June 30, 2011, BD Biosciences revenues increased by 5.7 percent, or 2.7 percent on a foreign currency-neutral basis.

Geographic Results

Third quarter revenues in the U.S. were $855 million, representing an increase of 5.7 percent compared with the prior-year period. Revenues outside of the U.S. were $1.159 billion, representing an increase of 13.4 percent compared with the prior-year period, or 4.1 percent on a foreign currency-neutral basis. Revenues reflected continued strength in emerging markets, which was partially offset

by ongoing challenging macroeconomic conditions in Western Europe. For the nine-month period ended June 30, 2011, revenues in the U.S. were $2.513 billion, representing an increase of 2.4 percent compared with the prior-year period. Revenues outside of the U.S. were $3.265 billion, representing an increase of 7.2 percent compared with the prior-year period, or 2.8 percent on a foreign currency-neutral basis.

Fiscal Year 2011 Outlook

Reported revenue growth guidance for the full fiscal year 2011 is expected to be at the higher end of the previously communicated range of 5 to 6 percent compared with fiscal year 2010, due to the anticipated effects of favorable currency. On a foreign currency-neutral basis, the Company is lowering its revenue growth guidance to an increase of about 3 percent versus its previously communicated guidance of about 3.5 percent, mainly due to lower than expected sales in Western Europe.

The Company is raising its previous guidance for reported diluted earnings per share from continuing operations for fiscal year 2011 from $5.55-$5.65 to $5.65-$5.70, an increase of approximately 15 to 16 percent over fiscal year 2010, due to the anticipated effects of favorable currency. Diluted earnings per share from continuing operations for fiscal year 2011 are expected to increase 14 to 15 percent over adjusted diluted earnings per share from continuing operations of $4.94, excluding the specified item, for fiscal year 2010. The specified item represents the aforementioned 2010 non-cash charge of $0.04 per share related to healthcare reform. On a currency-neutral basis, the Company continues to expect diluted earnings per share from continuing operations to increase about 10 percent over adjusted diluted earnings per share in the prior-year period, despite lower than expected revenue growth and higher resin costs.

Conference Call Information

A conference call regarding BD’s third quarter results and its expectations will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Tuesday, August 2, 2011. The slides are available concurrent with the issuance of this press release at www.bd.com/investors. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 855-859-2056 (domestic) and 404-537-3406 (international) through the close of business on Tuesday, August 9, 2011, access code 82566570.

Non-GAAP Financial Measures

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled “Fiscal Year 2011 Outlook”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. Forward-looking statements may be identified by the use of words such as “expect”, “estimate” or words of similar meaning in conjunction with statements of future performance. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the potential adverse effects that the earthquake and tsunami in Japan and the situation regarding the Fukushima, Japan nuclear power plant may have on BD’s future operations in Japan; the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for BD’s products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic situation on BD’s ability to access credit markets and finance its operations, the demand for BD’s products and services, or its suppliers’ ability to provide products needed for BD’s operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting BD’s business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; BD’s ability to successfully integrate any businesses it acquires; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. BD does not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

		Three Months Ended June 30,
		2011				2010				%Change
REVENUES		$	2,014,081			$	1,830,911				10.0
Cost of products sold			951,980				883,434				7.8
Selling and administrative			474,646				416,468				14.0
Research and development			115,748				108,047				7.1
TOTAL OPERATING COSTS AND EXPENSES			1,542,374				1,407,949				9.5
OPERATING INCOME			471,707				422,962				11.5
Interest income			11,508				2,094			NM
Interest expense			(22,211	)			(13,085	)			69.7
Other (expense) income, net			(363	)			1,402			NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			460,641				413,373				11.4
Income tax provision			122,531				119,213				2.8
INCOME FROM CONTINUING OPERATIONS			338,110				294,160				14.9
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $111 AND $4,340, RESPECTIVELY			4,948				12,748				(61.2	)
NET INCOME		$	343,058			$	306,908				11.8
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	1.54			$	1.26				22.2
Income from discontinued operations		$	0.02			$	0.05				(60.0	)
Net income (1)		$	1.57			$	1.32				18.9
Diluted:
Income from continuing operations		$	1.51			$	1.23				22.8
Income from discontinued operations		$	0.02			$	0.05				(60.0	)
Net income (1)		$	1.53			$	1.29				18.6
AVERAGE SHARES OUTSTANDING
Basic			218,966				233,242
Diluted			223,567				238,319

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

		Nine Months Ended June 30,
		2011				2010				%Change
REVENUES		$	5,778,109			$	5,499,138				5.1
Cost of products sold			2,738,000				2,642,250				3.6
Selling and administrative			1,364,543				1,283,217				6.3
Research and development			350,441				307,391				14.0
TOTAL OPERATING COSTS AND EXPENSES			4,452,984				4,232,858				5.2
OPERATING INCOME			1,325,125				1,266,280				4.6
Interest income			41,294				20,535			NM
Interest expense			(61,685	)			(38,985	)			58.2
Other expense, net			(7,481	)			(788	)		NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES			1,297,253				1,247,042				4.0
Income tax provision			333,804				363,755				(8.2	)
INCOME FROM CONTINUING OPERATIONS			963,449				883,287				9.1
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF $711 AND $13,058, RESPECTIVELY			7,566				37,628				(79.9	)
NET INCOME		$	971,015			$	920,915				5.4
EARNINGS PER SHARE
Basic:
Income from continuing operations		$	4.33			$	3.75				15.5
Income from discontinued operations		$	0.03			$	0.16				(81.3	)
Net income		$	4.36			$	3.91				11.5
Diluted:
Income from continuing operations		$	4.23			$	3.66				15.6
Income from discontinued operations		$	0.03			$	0.16				(81.3	)
Net income		$	4.26			$	3.82				11.5
AVERAGE SHARES OUTSTANDING
Basic			222,674				235,316
Diluted			227,782				241,151

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

		Three Months Ended June 30,
		2011				2010				%Change
BD MEDICAL
United States		$	416,729			$	381,761				9.2
International			628,107				563,761				11.4
TOTAL		$	1,044,836			$	945,522				10.5
BD DIAGNOSTICS
United States		$	312,802			$	303,521				3.1
International			318,557				272,748				16.8
TOTAL		$	631,359			$	576,269				9.6
BD BIOSCIENCES
United States		$	125,933			$	124,146				1.4
International			211,953				184,974				14.6
TOTAL		$	337,886			$	309,120				9.3
TOTAL REVENUES
United States		$	855,464			$	809,428				5.7
International			1,158,617				1,021,483				13.4
TOTAL		$	2,014,081			$	1,830,911				10.0

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

		Nine Months Ended June 30,
		2011				2010				%Change
BD MEDICAL
United States		$	1,220,744			$	1,196,105				2.1
International			1,731,969				1,641,722				5.5
TOTAL		$	2,952,713			$	2,837,827				4.0
BD DIAGNOSTICS
United States		$	932,269			$	906,566				2.8
International			906,160				820,849				10.4
TOTAL		$	1,838,429			$	1,727,415				6.4
BD BIOSCIENCES
United States		$	360,234			$	351,933				2.4
International			626,733				581,963				7.7
TOTAL		$	986,967			$	933,896				5.7
TOTAL REVENUES
United States		$	2,513,247			$	2,454,604				2.4
International			3,264,862				3,044,534				7.2
TOTAL		$	5,778,109			$	5,499,138				5.1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)

		United States
		2011				2010				%Change
BD MEDICAL
Medical Surgical Systems		$	244,756			$	239,866				2.0
Diabetes Care			100,465				96,071				4.6
Pharmaceutical Systems			71,508				45,824				56.0
TOTAL		$	416,729			$	381,761				9.2
BD DIAGNOSTICS
Preanalytical Systems		$	162,589			$	159,228				2.1
Diagnostic Systems			150,213				144,293				4.1
TOTAL		$	312,802			$	303,521				3.1
BD BIOSCIENCES
Cell Analysis		$	89,162			$	84,365				5.7
Discovery Labware			36,771				39,781				(7.6	)
TOTAL		$	125,933			$	124,146				1.4
TOTAL UNITED STATES		$	855,464			$	809,428				5.7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

		International
										% Change
		2011				2010				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	284,262			$	253,687				12.1				3.0				9.1
Diabetes Care			119,719				101,081				18.4				7.8				10.6
Pharmaceutical Systems			224,126				208,993				7.2				(1.8	)			9.0
TOTAL		$	628,107			$	563,761				11.4				2.1				9.3
BD DIAGNOSTICS
Preanalytical Systems		$	167,737			$	144,298				16.2				6.0				10.2
Diagnostic Systems			150,820				128,450				17.4				7.5				9.9
TOTAL		$	318,557			$	272,748				16.8				6.7				10.1
BD BIOSCIENCES
Cell Analysis		$	165,866			$	146,068				13.6				5.5				8.1
Discovery Labware			46,087				38,906				18.5				8.9				9.6
TOTAL		$	211,953			$	184,974				14.6				6.2				8.4
TOTAL INTERNATIONAL		$	1,158,617			$	1,021,483				13.4				4.1				9.3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

		Total
										% Change
		2011				2010				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	529,018			$	493,553				7.2				2.5				4.7
Diabetes Care			220,184				197,152				11.7				6.2				5.5
Pharmaceutical Systems			295,634				254,817				16.0				8.6				7.4
TOTAL		$	1,044,836			$	945,522				10.5				4.9				5.6
BD DIAGNOSTICS
Preanalytical Systems		$	330,326			$	303,526				8.8				4.0				4.8
Diagnostic Systems			301,033				272,743				10.4				5.7				4.7
TOTAL		$	631,359			$	576,269				9.6				4.8				4.8
BD BIOSCIENCES
Cell Analysis		$	255,028			$	230,433				10.7				5.6				5.1
Discovery Labware			82,858				78,687				5.3				0.6				4.7
TOTAL		$	337,886			$	309,120				9.3				4.3				5.0
TOTAL REVENUES		$	2,014,081			$	1,830,911				10.0				4.8				5.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)

		United States
		2011				2010				%Change
BD MEDICAL
Medical Surgical Systems		$	733,582			$	751,032				(2.3	)
Diabetes Care			295,989				285,150				3.8
Pharmaceutical Systems			191,173				159,923				19.5
TOTAL		$	1,220,744			$	1,196,105				2.1
BD DIAGNOSTICS
Preanalytical Systems		$	481,624			$	465,395				3.5
Diagnostic Systems			450,645				441,171				2.1
TOTAL		$	932,269			$	906,566				2.8
BD BIOSCIENCES
Cell Analysis		$	252,423			$	240,152				5.1
Discovery Labware			107,811				111,781				(3.6	)
TOTAL		$	360,234			$	351,933				2.4
TOTAL UNITED STATES		$	2,513,247			$	2,454,604				2.4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

		International
										% Change
		2011				2010				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	812,752			$	756,963				7.4				2.1				5.3
Diabetes Care			345,837				301,508				14.7				9.6				5.1
Pharmaceutical Systems			573,380				583,251				(1.7	)			(3.5	)			1.8
TOTAL		$	1,731,969			$	1,641,722				5.5				1.5				4.0
BD DIAGNOSTICS
Preanalytical Systems		$	467,570			$	425,967				9.8				4.6				5.2
Diagnostic Systems			438,590				394,882				11.1				5.7				5.4
TOTAL		$	906,160			$	820,849				10.4				5.2				5.2
BD BIOSCIENCES
Cell Analysis		$	498,864			$	464,091				7.5				3.1				4.4
Discovery Labware			127,869				117,872				8.5				2.3				6.2
TOTAL		$	626,733			$	581,963				7.7				2.9				4.8
TOTAL INTERNATIONAL		$	3,264,862			$	3,044,534				7.2				2.8				4.4

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

		Total
										% Change
		2011				2010				Reported				FXN				FX Impact
BD MEDICAL
Medical Surgical Systems		$	1,546,334			$	1,507,995				2.5				(0.1	)			2.6
Diabetes Care			641,826				586,658				9.4				6.8				2.6
Pharmaceutical Systems			764,553				743,174				2.9				1.5				1.4
TOTAL		$	2,952,713			$	2,837,827				4.0				1.7				2.3
BD DIAGNOSTICS
Preanalytical Systems		$	949,194			$	891,362				6.5				4.0				2.5
Diagnostic Systems			889,235				836,053				6.4				3.8				2.6
TOTAL		$	1,838,429			$	1,727,415				6.4				3.9				2.5
BD BIOSCIENCES
Cell Analysis		$	751,287			$	704,243				6.7				3.8				2.9
Discovery Labware			235,680				229,653				2.6				(0.5	)			3.1
TOTAL		$	986,967			$	933,896				5.7				2.7				3.0
TOTAL REVENUES		$	5,778,109			$	5,499,138				5.1				2.6				2.5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)

		Three Months Ended June 30,
										% Change
		2011				2010				Reported				FXN				FX Impact
TOTAL SAFETY REVENUES
United States		$	280,696			$	270,604				3.7				3.7				—
International			198,417				157,851				25.7				14.1				11.6
TOTAL		$	479,113			$	428,455				11.8				7.6				4.2
BY SEGMENT
BD Medical		$	223,460			$	195,400				14.4				10.4				4.0
BD Diagnostics			255,653				233,055				9.7				5.2				4.5
TOTAL		$	479,113			$	428,455				11.8				7.6				4.2

		Nine Months Ended June 30,
										% Change
		2011				2010				Reported				FXN				FX Impact
TOTAL SAFETY REVENUES
United States		$	828,002			$	825,463				0.3				0.3				—
International			545,530				461,517				18.2				11.9				6.3
TOTAL		$	1,373,532			$	1,286,980				6.7				4.5				2.2
BY SEGMENT
BD Medical		$	641,635			$	610,262				5.1				3.0				2.1
BD Diagnostics			731,897				676,718				8.2				5.8				2.4
TOTAL		$	1,373,532			$	1,286,980				6.7				4.5				2.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
FY2011 Year-to-Date Reconciliation
(Unaudited; Amounts in millions, except per share data)

		Nine Months Ended June 30,
		Reported				Reported								Adjusted				Adjusted
		FY 2011				FY 2010				Tax (1)				FY 2010				%Growth
Diluted Earnings per Share
from Continuing Operations		$	4.23			$	3.66			$	0.04			$	3.70				14.3	%

(1)		Represents a non-cash charge related to healthcare reform impacting Medicare Part D reimbursements.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Quarter-to-Date Fiscal 2011 Reconciliation — FX Impact
(Unaudited; Amounts in millions, except per share data)

		Three Months Ended June 30,
		Reported				Reported				Reported Growth				Foreign Currency				FY10 Hedge				Total				FXN				FXN
		FY 2011				FY 2010				$				Translation				Loss				FX				Change				Growth
REVENUES		$	2,014			$	1,831			$	183			$	94			$	1			$	96			$	88				4.8	%
Diluted Earnings per Share from Continuing Operations		$	1.51			$	1.23			$	0.28			$	0.11			$	0.00			$	0.11			$	0.17				13.8	%

         All figures rounded. Totals may not add due to rounding.

         FXN = Foreign Currency Neutral

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

Year-to-Date Fiscal 2011 Reconciliation — FX Impact

(Unaudited; Amounts in millions, except per share data)

		Nine Months Ended June 30,
										Adjusted				Foreign				FY10									Adjusted
		Reported				Adjusted				Growth				Currency				Hedge					Total				FXN				FXN
		FY 2011				FY 2010				$				Translation				Loss					FX				Change				Growth
REVENUES		$	5,778			$	5,499			$	279			$	94			$	43			$	136			$	143				2.6	%
Diluted Earnings per Share
from Continuing Operations		$	4.23			$	3.70			$	0.53			$	0.12			$	0.11			$	0.23			$	0.30				8.1	%

     All figures rounded. Totals may not add due to rounding.

     FXN = Foreign Currency Neutral

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2010 Total Year Reconciliation

Reported Diluted Earnings per Share from Continuing Operations		$	4.90
Tax (1)			0.04
Adjusted Diluted Earnings per Share from Continuing Operations		$	4.94